BioLattice

Revolutionizing Tissue Repair

Company details

BioLattice is on a mission to end corneal blindness. Only 1 in 70 patients who need cornea tissue get access to it. Globally 2 million per year suffer from corneal blindness while only 200,000 per year receive vision restoration through corneal transplants. Over 12 million worldwide are on a donor cornea tissue waiting list, and those with access to donor cornea face challenges including a 10% chance of implant failure within year 1. Even with immunosuppressant drops needed after surgery, the chances of rejection still rise to almost 50% by year 15 with the risk of going blind again. Our engineered cornea, CorneaClearTM, is a synthetic room temperature stable material that will restore AND correct vision. CorneaClearTM will disrupt the standard of care of donor cornea tissue usage in full thickness corneal transplants.

Worldwide, there’s only one donor cornea for every 70 people who need a corneal transplant to restore their vision.

BioLattice Quote Image
Amelia Zellander, PhD, founder and CSO
We’re developing alternatives to donated tissues and organs. So many people either have low quality of life or unnecessarily short lives because the system in place just doesn't work for everyone. So, I want to do something in my career that fixes this altogether.

Team

Amelia Zellander

CSO

Linda Alunkal

CEO

Get In Touch with BioLattice

Please tell us a little bit about yourself and why you'd like to get connected. BioLattice + SOSV will follow up with you via email.

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.